A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber Cancer Institute report.
Cancer researchers led by Dr. John Dick at Ontario Cancer Institute (OCI) have developed a method to convert normal human blood cells into ?human? leukemia stem cells.
An international research team, led by investigators from the Massachusetts General Hospital (MGH) Cancer Center and Dana-Farber Cancer Institute (DFCI), has found a new way that some lung tumors become resistant to treatment with targeted therapy drugs like Iressa and Tarceva.
The American Gastroenterological Association (AGA) Institute is eager to increase the number of patients who receive screening for colon cancer. There are a variety of established screening methods that are widely available, and emerging technologies, such as computed tomography colonography (CT colonography), that are under investigation.
There is no evidence that antioxidant supplements interfere with the therapeutic effects of chemotherapy agents, according to a recent systematic review of the use of antioxidants during chemotherapy, available in the May, 2007 issue of the peer-reviewed journal Cancer Treatment Reviews.
Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center have developed methods for treating lung cancer cells that have become resistant to new anti-cancer agents.
A new study says targeting smaller (??5 mm) lesions does little to significantly reduce the incidence of colorectal cancer (CRC) and, in fact, results in extremely high financial costs and a large proportion of adverse events.
Correcting social, economic and health-care inequalities may have the most significant impact in reducing survival differences in colorectal cancer between African-Americans and Caucasians, according to a new study.
A report of data from the National Cancer Institute?s Surveillance Epidemiology and End Results (SEER) database published in the New England Journal of Medicine, suggests that a decline in breast cancer incidence may be caused by a drop in hormone therapy use during the same time period.
Colon cancer could join the growing list of stem cell-related cancers with the discovery of a population of highly tumorigenic primary human colon tumor cells, according to researchers from Biogen Idec.